Francisco Badia
Managing Partner @ Grow Venture Partners
Barcelona, Spain
Francisco Badia is a seed investor at Grow Venture Partners in Barcelona focused on Software and Health Care. He is a Managing partner at GROW Venture Partners. He completed his education at Universitat Politècnica de Catalunya.
- Total investments:
- 8
- Last investment:
- Lead investor:
- 75%
Last updated:
For AI agents: llms.txt
Industries Francisco Badia invests in
Stages Francisco Badia invests in
Countries Francisco Badia invests in
Investment Focus
Industry
- Software 2 (25%)
- Health Care 2 (25%)
- Artificial Intelligence 2 (25%)
- Chemical 1 (13%)
- Training 1 (13%)
Stage
- Seed 3 (38%)
- Pre-Seed 2 (25%)
- Venture - Series Unknown 2 (25%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
X1 Wind
|
X1 Wind is a disruptive floating platform developing a floating wind platform for deep waters. The platform has redesigned floating wind platforms to reduce costs by 50percent and weight 80percent while expanding the operation depth range in comparison to other floating solutions. It has less active systems than current designs and can be fullyassembled at the port and then installed using a small tug boat.X1 Wind helps to achieve a radical weight reduction in floating wind structures to current semi-submersible and spar systems. It was founded in 2017 and is based in Barcelona, Spain. | $5.1M / Seed / Jul 01, 2026 | |
The Blue Box Biomedical Solutions
|
Women aged 20-45 cannot get screened for breast cancer because existing solutions are unreliable. However, 81% want to. At The Blue Box, we have built a pain-free, low-cost, sensitive, radiation-free device to detect breast cancer in urine with a sensitivity of 83%. In 2024, we’ll launch into the market, bringing The Blue Box to private gynecologyclinics with a Diagnostics-as-a-Service subscription model, and a pay-per-test revenue stream that we’ll share with doctors. | $3.8M / Seed / Nov 18, 2025 | |
|
The Blue Box Biomedical Solutions
|
Women aged 20-45 cannot get screened for breast cancer because existing solutions are unreliable. However, 81% want to. At The Blue Box, we have built a pain-free, low-cost, sensitive, radiation-free device to detect breast cancer in urine with a sensitivity of 83%. In 2024, we’ll launch into the market, bringing The Blue Box to private gynecologyclinics with a Diagnostics-as-a-Service subscription model, and a pay-per-test revenue stream that we’ll share with doctors. | $549K / Seed / Jul 29, 2024 | |
Nextmol
|
Nextmol is a Barcelona-based startup specialized in computational chemistry. It develops a software platform to accelerate the design of new chemicals through molecular modeling and artificial intelligence for a more efficient R&D. Nextmol shortens the path to chemical innovation over the traditional lab approach thanks to its ability toperform unlimited testing via computations. Furthermore, computations provide key insights about the physico-chemical behavior of the candidate molecules. Nextmol is a spin-off company of the Barcelona Supercomputing Center, one of the largest supercomputing facilities in Europe. | Venture - Series Unknown / May 27, 2024 | |
Virmedex
|
Virmedex creates gamified software for virtual training platforms and e-learning. | $162.4K / Pre-Seed / Feb 22, 2024 | |
teknoCEA
|
teknoCEA offers power electronics systems, components, and services to power systems, automation, and power electronics-related businesses and research labs. Their primary goal is to assist businesses in accelerating the projects, research, and application of power electronics technology. | $217.7K / Venture - Series Unknown / Dec 13, 2023 | |
Floatech
|
Floatech develops high-performance silicon anodes for advanced technology industries. Their proprietary process yields high-performance qualities in LIBs while combining manufacturing sustainability and scalability. | $1.3M / Seed / Nov 24, 2023 | |
Tirecat
|
Tirecat specialized in developing sophisticated tissue regeneration treatments to combat chronic and terminal diseases. | $177.3K / Pre-Seed |
Co-Investors
About Grow Venture Partners
Grow Venture Partners is a venture capital firm.
Grow Venture Partners Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Francisco Badia
Managing Partner
|
|||
4 more contacts available
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Francisco Badia invest in?
Francisco Badia invests primarily in Software, Health Care and Artificial Intelligence startups, most often at Seed and Pre-Seed stage. Most of the 8 investments tracked by Shizune back companies in Spain. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Francisco Badia last invest?
The most recent investment recorded for Francisco Badia closed in Jul 2026. Shizune tracks 8 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
